Tel.: +216-368-0330, Fax: +216-368-3055
Early Detection and Diagnosis
Single cell molecular recognition of migrating and invading tumor cells using a targeted fluorescent probe to receptor PTPmu†
Version of Record online: 11 OCT 2012
Copyright © 2012 UICC
International Journal of Cancer
Volume 132, Issue 7, pages 1624–1632, 1 April 2013
How to Cite
Burden-Gulley, S. M., Qutaish, M. Q., Sullivant, K. E., Tan, M., Craig, S. E.L., Basilion, J. P., Lu, Z.-R., Wilson, D. L. and Brady-Kalnay, S. M. (2013), Single cell molecular recognition of migrating and invading tumor cells using a targeted fluorescent probe to receptor PTPmu. Int. J. Cancer, 132: 1624–1632. doi: 10.1002/ijc.27838
Conflict of interest: Dr. Wilson has a financial interest in BioInVision Inc., which is commercializing cryo-imaging.
- Issue online: 28 JAN 2013
- Version of Record online: 11 OCT 2012
- Accepted manuscript online: 14 SEP 2012 06:07AM EST
- Manuscript Accepted: 16 AUG 2012
- Manuscript Received: 7 MAR 2012
- NIH. Grant Numbers: R01-NS063971, R42-CA124270, P30-CA043703
- Biomedical Structure, Functional and Molecular Imaging Enterprise (D.W.)
- NIH. Grant Numbers: R01-NS063971, R42-CA124270, P30 CA43703
- Ohio Wright Center/BRTT
- Biomedical Structure, Functional and Molecular Imaging Enterprise
- Case Center for Imaging Research and the Tabitha Yee-May Lou Endowment Fund for Brain Cancer Research
- receptor protein tyrosine phosphatase;
- proteolytic cleavage;
- molecular imaging;
- targeting agent;
Detection of an extracellular cleaved fragment of a cell–cell adhesion molecule represents a new paradigm in molecular recognition and imaging of tumors. We previously demonstrated that probes that recognize the cleaved extracellular domain of receptor protein tyrosine phosphatase mu (PTPmu) label human glioblastoma brain tumor sections and the main tumor mass of intracranial xenograft gliomas. In this article, we examine whether one of these probes, SBK2, can label dispersed glioma cells that are no longer connected to the main tumor mass. Live mice with highly dispersive glioma tumors were injected intravenously with the fluorescent PTPmu probe to test the ability of the probe to label the dispersive glioma cells in vivo. Analysis was performed using a unique three-dimensional (3D) cryo-imaging technique to reveal highly migratory and invasive glioma cell dispersal within the brain and the extent of colabeling by the PTPmu probe. The PTPmu probe labeled the main tumor site and dispersed cells up to 3.5 mm away. The cryo-images of tumors labeled with the PTPmu probe provide a novel, high-resolution view of molecular tumor recognition, with excellent 3D detail regarding the pathways of tumor cell migration. Our data demonstrate that the PTPmu probe recognizes distant tumor cells even in parts of the brain where the blood–brain barrier is likely intact. The PTPmu probe has potential translational significance for recognizing tumor cells to facilitate molecular imaging, a more complete tumor resection and to serve as a molecular targeting agent to deliver chemotherapeutics to the main tumor mass and distant dispersive tumor cells.
Glioblastoma multiforme (GBM) is the most common malignant adult astrocytoma with very low short- and long-term survival rates.1 It is characterized as having a necrotic main tumor mass accompanied by high dispersal of individual or clusters of tumor cells along blood vessels and white matter tracts in the brain. Currently, the best treatment for GBM is surgical resection of the main tumor mass, followed by radiotherapy and temozolomide chemotherapy.2 The extent of surgical resection of the main tumor mass has a significant effect on overall survival,3–5 especially when combined with radiotherapy and chemotherapy.4 Magnetic resonance imaging (MRI) is currently used to delineate the tumor border before tumor resection. Unfortunately, this is an imperfect tool, as the contrast enhancement agent, gadolinium, has highly variable labeling results and cannot highlight individual GBM cells that have migrated away from the main tumor mass,6 nor can a static image taken before surgery be used as a real-time intraoperative guide. Imaging of the dispersed tumor cell population in addition to the main tumor mass before surgery would provide a significant advantage to the surgeon.
The development of tools to molecularly label tumor cells to aid in surgical resection is a major focus of current cancer research.7 To this end, we have studied a cleaved and shed extracellular fragment of the receptor protein tyrosine phosphatase mu (PTPµ) that is found in the tumor microenvironment. Full-length PTPµ has both cell adhesion and signaling capabilities. The extracellular segment of full-length PTPµ has a MAM (meprin, A5/neuropilin and mu) domain, an immunoglobulin (Ig) domain and four fibronectin type III (FNIII) repeats. The MAM and Ig domains as well as the first two FNIII repeats are required for efficient cell–cell adhesion.8–14 The intracellular segment of full-length PTPµ has two tyrosine phosphatase domains15 of which only the membrane proximal tyrosine phosphatase domain is catalytically active.16
PTPµ extracellular fragment is detected in human GBM tissue and in glioma cells.17,18 It consists of the MAM, Ig and first two FNIII repeats of full-length PTPµ,18 and thus should be able to bind homophilically to other PTPµ molecules. PTPµ is cleaved either by a matrix metalloprotease (MMP) or by A Disintegrin And Metalloprotease (ADAM) to yield the PTPµ extracellular segment and a membrane-tethered fragment consisting of the transmembrane and intracellular domains.17 The membrane-tethered fragment is subsequently cleaved by the gamma secretase complex to give rise to a membrane-free intracellular fragment capable of translocating to the cell nucleus where it remains catalytically active.17
Fluorescently labeled targeted PTPµ peptide probes capable of binding homophilically to the shed PTPµ extracellular fragment label tumor cells in sections taken from human GBM tissue, whereas scrambled versions of these probes do not bind tumors.18 The edge samples of human GBM tumors contain the PTPµ extracellular fragment and are labeled by these probes.18 However, the PTPµ probes do not bind endogenous full-length PTPµ in the normal (epileptic) brain, likely because of steric hindrance induced by the engagement of full-length PTPµ–PTPµ homophilic binding.18 The most effective of the fluorescently labeled PTPµ probes, SBK2 and SBK4, can also label flank and intracranial xenograft tumors of human glioma cells when injected into the tail vein of nude mice.18 Although the main tumor mass and the tumor edge could be labeled with the probes in vivo, the probes were not tested in an invasive/dispersive model. As conventional imaging techniques such as MRI are limited to visualizing the main tumor mass, we examined the ability of the PTPµ probe to label migrating and dispersive cells that have moved away from the main tumor mass.
To evaluate tumor cell dispersal in the complex architecture of the adult brain, we developed a cryo-imaging system and analysis algorithms that create a three-dimensional (3D) rendering of fluorescently labeled cells in both the main tumor and in dispersed cells.19,20 Using this cryo-imaging system, we identified two highly dispersive cell lines, CNS-1 rat glioma cells and LN-229 human glioma cells, that form intracranial tumors much like those observed in human GBM, with large populations of dispersive cells that migrate great distances along both blood vessels and white matter tracts.20 Because of the resolution of the cryo-imaging system, single fluorescently labeled cells can be visualized in three dimensions in the brain.20
In our study, we evaluated the ability of the fluorescent PTPµ probe to label the adjacent microenvironment of dispersed cell populations of CNS-1-GFP and LN-229-GFP intracranial tumors as assayed using the 3D cryo-imaging system. Live mice bearing brain tumors were injected intravenously with the Cy5 PTPµ probe. Brains were imaged postmortem using whole-brain macroscopic fluorescence imaging and the cryo-imaging system.18–20 Fluorescent signals were analyzed to determine the colocalization of the Cy5-labeled PTPµ probe with the GFP-labeled dispersed tumor cells in the entire mouse brain. The 3D cryo-imaging system and analysis indicates that the PTPµ probe detected 99% of tumor cells at the main tumor site and in the dispersed cell population up to 3.5 mm from the main tumor. Therefore, the PTPµ imaging probe has potential translational significance for molecular imaging of tumors, guiding a more complete resection of tumors and to serve as a molecular targeting agent to deliver chemotherapeutics to the main tumor mass and distant dispersive tumor cells.
Material and Methods
Peptide synthesis and conjugation
The SBK2 peptide (GEGDDFNWEQVNTLTKPTSD) and a scrambled sequence of the SBK2 peptide (GFTQPETGTDNDLWSVDNEK) were synthesized using a standard Fmoc-based solid-phase strategy with an additional N-terminal glycine residue in the laboratory of Dr. Z.-R. Lu as previously described.18 After synthesis, the N-terminal glycine residues of the SBK2 and scrambled probes were conjugated to Cy5 NHS ester dye (GE Healthcare Life Sciences, Pittsburgh, PA).
Orthotopic xenograft intracranial tumors
Approved protocols from the Institutional Animal Care and Use Committee at Case Western Reserve University were followed for all animal procedures.
CNS-1 (a gift from Mariano S. Viapiano21) or LN-229 (American Type Culture Collection, Manassas, VA) cell lines were infected with GFP-encoding lentivirus and used for intracranial implantation in 4- to 6-week-old NIH athymic nude male mice (NCr-nu/+, NCr-nu/nu, 20–25 g each) as previously described.20 GFP fluorescence in 100% of cells was verified before use in intracranial implants. The CNS-1 cell line was authenticated by Research Animal Diagnostic Laboratory at the University of Missouri (Columbia, MO) for interspecies and mycoplasma contamination by PCR analysis. A total of 5 × 104 (LN-229) or 2 × 105 (CNS-1) cells were implanted per mouse.
In vivo labeling of intracranial tumors
Imaging experiments were performed at 10–11 days for CNS-1 and 4–8 weeks for LN-229 to allow for optimal tumor growth and cell dispersal of these two cell lines.18,20 Live mice were injected via lateral tail vein with either SBK2-Cy5 or scrambled-Cy5 probes diluted to 15 µM in PBS (3 nmol total probe delivered). After a 90-min interval for clearance of unbound probe, the animals were sacrificed and the brains were removed for whole-brain imaging using the Maestro™ FLEX In Vivo Imaging System [Cambridge Research & Instrumentation (CRi), Woburn, MA].18 Immediately after imaging, the brains were embedded in Tissue-Tek OCT compound (Sakura Finetek U.S.A., Torrance, CA), frozen in a dry ice/ethanol slurry and cryo-imaged. Of note, delivery of multiple doses of either the SBK2-Cy5 or scrambled-Cy5 probes did not result in deleterious effects on mouse health (data not shown).
Cryo-imaging of tissue samples
Frozen brains were alternately sectioned and imaged using the previously described Case Cryo-Imaging System19,20 at a section thickness of 15 µm and a resolution of 11 µm × 11 µm × 15 µm. Brightfield and fluorescence images were acquired for each of the brains using a low-light digital camera (Retiga Exi, QImaging, Surrey, British Columbia, Canada), an epi-illumination fluorescent light source (Lumen200 PRO, Prior Scientific, Rockland, MA) and fluorescence filters for GFP (Exciter: HQ470/40×, Dichroic: Q495LP, Emitter: HQ500LP) or Cy5 (Exciter: FF01-628/40-25, Dichroic: FF660-Di01-25 × 36, Emitter: FF01-692/40-25; Semrock, Rochester, NY). Single GFP-expressing cells were readily detected with this system. Brightfield and fluorescence exposure settings were identical for SBK2-Cy5 and scrambled-Cy5 probe-treated brains. Seven brains implanted with CNS-1-GFP cells and six brains with LN-229-GFP cells were analyzed.
Image processing algorithms for visualization of tumor cells and vasculature
Methodologies for segmentation and visualization of the main tumor mass, dispersing cells and vasculature have been described.19 Briefly, the main tumor mass was segmented using a fast 3D region growth algorithm with intensity and gradient-based inclusion/exclusion criteria. Individual slice images were manually edited if necessary. Dispersed cells and clusters were detected by thresholding a Gaussian high-pass filter image, discounting the masked main tumor mass. Autofluorescence of normal tissue is not a concern for false-positive signals in both red and green channels as it is only less than 1% of the signal found in the vicinity of the main tumor and dispersed cells. Light scattering in tissue might appear as a false-positive signal in Cy5 volumes. However, we processed Cy5 volumes with a next-image processing algorithm and used attenuation and scattering parameters for brain tissues that were previously described.22 Similar parameters were applied for both SBK2-Cy5 and scrambled-Cy5 volumes. To find colabeled cells/clusters, we applied a logical AND operator between the dispersed cell and a Cy5 volume made binary with a threshold. The system is not overly sensitive to variations in the threshold for creating the binary Cy5 volume. The lower limit for the blood vessel detection algorithm was ∼30 µm diameter. Three-dimensional volumes of tumor, dispersed cells, Cy5-labeled cells and vasculature were rendered using Amira software (Visage Imaging, San Diego, CA), with modifications developed expressly for cryo-image data. Pseudo-colors were chosen to give the best contrast between the different data volumes. Colors were green (main tumor), yellow (dispersing cells), pink (PTPµ probe-labeled dispersed cells) and red (vasculature).
Relative quantification of Cy5 fluorescence
Cy5 fluorescence intensity of tumors and dispersed cells was quantified by Matlab software using next-image processed volumes for CNS-1 and LN-229 tumors labeled with SBK2-Cy5 or scrambled-Cy5 probes, which normalized the signal to background fluorescence. Total fluorescence signal for each brain was then normalized for tumor volume. SBK2-Cy5 analysis: n = 4 tumors for CNS-1 and n = 5 tumors for LN-229. Scrambled-Cy5 analysis: n = 3 tumors for CNS-1 and n = 1 tumor for LN-229.
Distance analysis of SBK2-Cy5 probe-labeled dispersed cells
The distance between the main tumor mass and dispersed cells was determined using a 3D morphological distance algorithm.19 Briefly, the algorithm detects the presence of fluorescent voxels in a series of 3D dilations from the tumor edge outward. Voxel size was 11 µm × 11 µm × 15 µm, approximately the size of single cells. Dilations within 500 µm of the tumor edge were discarded to reduce nonspecific errors and to focus on the population of cells that had dispersed the greatest distance from the main tumor mass. Comparisons were made between the average dispersed cell population and the average SBK2-Cy5-labeled dispersed cell population for each 500 µm distance increment from a total of four brains.
Results from the morphological distance algorithm described above were segmented into incremental distances of 500 µm from the tumor edge, and averaged from four brains. The standard deviation was calculated in Excel from the range of all values within each plotted distance increment for the four brains. The standard error was calculated in Excel using the standard deviation for each data point shown.
A PTPµ-targeted probe was developed for the molecular recognition of glioma cells. Intracranial tumors of glioma cells expressing GFP were labeled with the PTPµ-targeted probe (SBK2-Cy5) or with a scrambled version of the PTPµ probe (scrambled-Cy5) through intravenous administration. The main tumors were brightly labeled with the SBK2-Cy5 probe in all cases examined, whereas the scrambled probe resulted in no significant signal above background within the tumor (Fig. 1). Ten-day CNS-1-GFP intracranial tumors were labeled in vivo with the PTPµ probe by intravenous injection for 90 min before sacrifice and postmortem imaging. This time frame for probe clearance was determined empirically to provide optimal signal to noise (background) ratio of Cy5 fluorescence. The results from the two-dimensional (2D) block face images demonstrate bright PTPµ probe fluorescence (Figs. 1g and 1k) within the main GFP-positive tumor (Figs. 1f and 1j) in all cases. Cy5 fluorescence signal from PTPµ probe labeling also closely corresponded with the pattern of cell dispersal away from the main tumor (Figs. 1h and 1l). In contrast, the scrambled probe did not appreciably label GFP-positive tumor cells above background (Figs. 1a–1c). Quantitation of Cy5 fluorescence intensity from the CNS-1 main tumors and dispersed cell populations labeled with the PTPµ probe was 84.2 ± 15.6 (n = 4 brains) compared to 7.2 ± 2.3 (n = 3 brains) for the scrambled probe.
The blood–brain barrier is thought to be leaky within the main tumor in humans, a feature that is required for agents such as gadolinium to contrast brain tumors against the normal brain background. We examined the blood–brain barrier integrity in our mouse model system by perfusing with dilute India Ink before removal of the brain containing a tumor. Vasculature of the perfused brain was contrasted black against the brain parenchyma, and blood vessels that coursed through the tumor were clearly defined. In addition, a small accumulation of India Ink was localized to the main tumor (arrowhead in Fig. 1d), suggesting leakiness of blood vessels confined to the main tumor. On the basis of this result, we hypothesize that regions distant from the tumor edge likely have an intact blood–brain barrier, suggesting that the PTPµ probe may be able to cross the blood–brain barrier to detect dispersing tumor cells.
The probe labeled brains were then subjected to cryo-imaging analysis (Fig. 2) as previously described.20 The cryo-imaging system obtained 2D, microscopic brightfield anatomical images, including vasculature, and multispectral fluorescence images of tumor and probe. We refined our previous method19 to segment and visualize the vasculature, main tumor mass and dispersing cells to highlight the PTPµ probe labeling of only the dispersive glioma cells and cell clusters (refer to Material and Methods section). Three-dimensional volumes were created for the main tumor mass (pseudo-colored green) and vasculature (pseudo-colored red). Glioma cells no longer physically connected in any dimension to the main tumor were pseudo-colored yellow to indicate tumor cell dispersal. To specifically visualize the PTPµ probe overlay in 3D, the population of dispersing cells that was colabeled with the PTPµ probe (Cy5 fluorescence) was pseudo-colored pink by the computer program.
The rat CNS-1 glioma cell line rapidly disperses to distances of several millimeters from the main tumor.20 A gradient of PTPµ probe fluorescence (Figs. 2c and 2g) was observed that encompasses the wave of GFP-positive cell dispersal from the tumor (Figs. 2b, 2f and 2j). Streams of CNS-1-GFP cells migrating along a defined structure were highlighted against the background tissue by the PTPµ probe (Figs. 2g, 2h, 2k and 2l).
We have previously shown by immunoblot that the dispersive edge region of human glioblastoma tumors accumulates the PTPµ extracellular fragment,20 even though the tumor edge is comprised of normal brain cells and some dispersed tumor cells. In our study, the PTPµ probe fluorescent signal was often brighter in the region of lower GFP fluorescence, which corresponds to the area of tumor cell dispersal, than it was in the main tumor, which has higher GFP fluorescence (Figs. 2b–2d and 2f–2h). This result suggests that the dispersed cells may have more cleaved PTPµ extracellular fragment deposited in their adjacent microenvironment than in the main tumor, as recognized by the PTPµ probe. A magnified version of that same brain at the midline region of the frontal pole (asterisk) shows that GFP dispersing cells (Fig. 2f) are labeled with the PTPµ probe (Cy5: Figs. 2g and 2h) in 2D block face images. Three-dimensional reconstruction of the tumors illustrates a GFP-positive main tumor (pseudo-colored green) with a large population of GFP-labeled cells that disperse in many directions (pseudo-colored yellow) (Figs. 2i and 2j). Analysis of the PTPµ probe labeling of GFP-positive dispersed cells (pseudo-colored yellow) with the binary Cy5 volume indicates that greater than 99% of the total dispersed cells were colabeled with the PTPµ probe (pseudo-colored pink) (Figs. 2k and 2l and 4). Evaluation of additional CNS-1-GFP intracranial tumors labeled with the PTPµ probe demonstrated that the probe was highly effective at labeling the dispersed cell population (Fig. 3). In the two examples shown, a substantial amount of cell dispersal is evident over the brain vasculature in many directions (Figs. 3c and 3h).
Further analysis of the PTPµ probe-labeled CNS-1 intracranial tumors was performed to determine how far away from the main tumor mass dispersed cells could be labeled with the probe. Four CNS-1 intracranial tumors were analyzed to determine the total number of the dispersing cell population that was colabeled with the PTPµ probe. The data were segmented into incremental distances of 500 µm from the tumor edge and then averaged from the four brains. Based on the algorithms, the results show that the PTPµ probe colabels 99% of the dispersed cells to a maximum distance of 3.5 mm from the tumor edge (Fig. 4). In fact, the PTPµ probe is able to label even the distant dispersed tumor cells in multiple directions many millimeters from the main tumor mass (Figs. 3d, 3e, 3i and 3j as well as 4).
LN-229-GFP intracranial tumors require a minimum of 4 weeks growth to exhibit appreciable tumor cell dispersal.20 Labeling of LN-229-GFP tumors with the PTPµ probe resulted in a bright Cy5 fluorescence signal within the main GFP-positive tumor, and labeling of greater than 99% of the dispersed cell population (Figs. 5a–5c). Quantitation of Cy5 fluorescence from the LN-229 main tumors and dispersed cell populations labeled with the PTPµ probe was 114.7 ± 25.9 (n = 5 brains) compared to 5.8 (n = 1 brain) for the scrambled probe. In rare instances, glioma cells were deposited in close proximity to the lateral ventricle, resulting in extensive spread of cells along the ventricular walls, leptomeningeal regions, within the brainstem and in brain parenchyma at the cerebral/cerebellar junction (3D reconstruction shown in Figs. 5j–5l). Fluorescent signal from the PTPµ probe colocalized with much of this dispersed cell population (Figs. 5d–5l).
Results from these experiments suggest that the PTPµ probe crosses the blood–brain barrier to label not only the main tumor mass but also the vast majority of the dispersed tumor cells at a range up to 3.5 mm away from the main tumor mass (Fig. 4). In contrast, the scrambled-Cy5 probe did not label tumors (Figs. 1a–1c). The PTPµ probe preferentially labeled the PTPµ extracellular fragment deposited in the adjacent tumor microenvironment of the dispersed cells (Figs. 1g and 1k). These results suggest that the PTPµ probe is a marker of the microenvironment of the main tumor, tumor edge and dispersing cells, and could be utilized for tumor imaging, a more complete surgical resection or could be a viable molecular targeting agent to deliver therapeutics.
Better detection tools for tumor imaging are needed. Molecular recognition of tumor cells would facilitate guided surgical resection. To achieve this goal, targeted imaging tools must specifically label tumor cells, not only in the main tumor but also along the edge of the tumor and in the small tumor cell clusters that disperse throughout the body. To further improve patient survival, probes for the targeted delivery of therapeutics must be developed. The use of the cryo-imaging system allows us to determine whether the PTPµ probe is able to label individual dispersing tumor cells at a great distance from the main tumor within the complex 3D environment of the brain. We demonstrate that the PTPµ fluorescent probe is a useful reagent for labeling the main tumor mass and migrating cells, offering a visible means of identifying the dispersed cell population thought to be responsible for tumor recurrence. The kinetics of the PTPµ probe binding to tumors after tail-vein injection demonstrate that it binds within minutes of administration and lasts for as long as 3 hr,18 thus providing a window of time for surgery. The PTPµ probe has a high tumor contrast compared to background, as shown in the cryo-images acquired with a low power objective. Microscopes used in surgical suites typically use higher power objectives with a greater numerical aperture. As there is a direct relationship between numerical aperture and fluorescence brightness, the signal-to-noise ratio of the SBK2-Cy5 probe would be further improved in the surgical setting. Clinical safety of the probe would need to be evaluated, but our preliminary findings show no toxicity of the probe. However, we have not performed any formal toxicology studies with the probe to date.
Greater than 50% of tumor volume resection has been shown to be achievable through fluorescence-guided resection of tumor tissue using the Aminolevulinic Acid (ALA)-Protoporphyrin IX (PpIX) system,3 which visualizes fluorescently detectable PpIX, produced as a result of exogenously introduced ALA.23 In addition to the ALA-PpIX system, other fluorescent labeling agents have been developed to label the main tumor (for review, see Ref. 24). Targeted fluorophores against the EGF receptor type II (EGFR2/HER2) and VEGF receptors as well as folate receptor α have been used to intraoperatively label xenograft models of breast, ovarian and gastric cancers (in the case of HER2 and VEGFR)25 and ovarian cancer (in the case of the folate receptor α).26 Protease activatable fluorophores have also been used to detect tumor cells.24 For example, the protease cathepsin is enriched in the tumor microenvironment. A cathepsin-activated near-infrared fluorescent probe is effective at intraoperatively labeling breast cancer cells in a rat tumor model.27 An activatable cell-penetrating peptide (ACPP) conjugated to Cy5 is taken up by cancer cells only after proteolytic cleavage by MMPs 2 or 9.28, 29 The use of the ACPP-Cy5 probe as an intraoperative guide for surgery in mouse tumor models resulted in fewer cancer cells being left behind and better tumor-free and overall survival than in mice that underwent surgery without the fluorescent probe as a guide.28
The ALA-PpIX system has significant clinical utility in surgical resection of GBM, but its use results in only 50.2% of patients having complete tumor resection.5 It is unclear why only 50% of the patients respond. This may be the limit for improving upon surgical resection of brain tumors, but we hypothesize that better detection of dispersive cells in GBM would enhance the ability to completely resect a tumor. Although the ACPP-Cy5 probe is promising for tumor labeling outside of the brain,28 the addition of a large molecular weight carrier to the ACPP (ACPP-D) to facilitate tumor uptake and reduce background fluorescence produces a molecule that may be too large, ∼28 kDa,30 to cross the blood–brain barrier. We hypothesize that the PTPµ probe could be an improvement upon existing intraoperative labeling technologies because of its small size (∼3 kDa) and its ability to label virtually all of the highly dispersive cells that are characteristic of GBM, the very cells that are responsible for recurrence and the terminal nature of the disease.
Probes designed to label molecules that accumulate in the tumor microenvironment may also be advantageous as therapeutic targeting agents, as they can identify both the main tumor cell population and areas with infiltrating cells that contribute to tumor recurrence. The PTPµ probe labels the shed PTPµ extracellular fragment that accumulates in the tumor microenvironment, but is not present in normal brain.18 For this reason, the PTPµ probe could also be used to deliver therapeutics to the tumor microenvironment, including chemotherapy, directly to all tumor and any infiltrating stromal cells. The animals were sacrificed 90 min after probe injection, a time interval too short to observe any biological effects of the probe. It is currently unknown whether use of the PTPµ probe affects tumor cell dispersal/invasion. Future studies will address the long-term clearance and biological effects of the probes in vivo. The ability to directly target the tumor microenvironment would increase both the specificity and sensitivity of current treatments, therefore reducing nonspecific side effects of chemotherapeutics that affect all cells of the body.
Cleavage of many cell surface proteins by ADAM and/or MMPs occurs in tumor tissue31,32 and is likely due to the increased expression of proteases in the adjacent tumor microenvironment, especially at tumor margins.33 The techniques described for the development of fluorescently labeled PTPµ probes may also be used to develop probes to other proteins that are cleaved in GBM and other tumor types.31
The authors thank Debashish Roy, Lebing Li and Scott Becka for excellent technical assistance. This research was supported by the following NIH grants: R01-NS063971 (S.B.-K., J.P.B., Z.-R.L. and D.W.), R42-CA124270 (D.W.) and P30-CA043703 (S.B.-K. and J.P.B). This work was also supported by grant from the Biomedical Structure, Functional and Molecular Imaging Enterprise (D.W.).
- 5Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008; 62: 564–76;Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008; 62: 564–76., , , et al.